Six biotechs gear up to go public; Feds take a hard look at Teva;

@FierceBiotech: Can Sanofi's partnership with Regeneron redeem the French biotech's R&D reputation? Read | Follow @FierceBiotech

@JohnCFierce: J&J team marks another setback on depression as mid-stage study flops. Story | Follow @JohnCFierce

@DamianFierce: Merck takes aim at Sanofi with a Lantus biosimilar of its own. More | Follow @DamianFierce

@EmilyMFierce: Gates Foundation delivers an $11.8M grant to fuel tuberculosis R&D. News | Follow @EmilyMFierce

> After last week's 8 successful biotech IPOs, another 6 life sciences companies are expected to go public this week. More

> Federal prosecutors in New York are looking into Teva's ($TEVA) marketing practices for Copaxone and Azilect, investigating possible violations of the False Claims Act, according to Bloomberg. Article

> Sarepta ($SRPT) is touting positive safety results for AVI-7288, a Phase I treatment for the bioterror agent Marburg virus infection. News

Medical Device News

@FierceMedDev: Hackers broke into the Big 3--and left the door open for months, report says. Story | Follow @FierceMedDev

@MarkHFierce: Yes, med tech industry, you should watch India's regulatory reform process, but regulators aren't exactly rushing. Item | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Check out our special report: The top drug delivery partnerships of 2013. Report from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Researchers at Harvard and MIT develop innovative hearing aid chip. More | Follow @EmilyWFierce

> WSJ: Device VC funding drops to 8-year lows, but seeds are in place for a rebound. Story

> Roche + Cancer Genetics will expand cancer molecular Dx testing into warmer waters. Article

> Medtronic faces another pretrial setback over its Infuse bone growth implant. News

Pharma News

@FiercePharma: Feds put Teva's Copaxone, Azilect marketing under FCA microscope. Story | Follow @FiercePharma

@TracyStaton: Best-read story this AM in FiercePharma: FDA panel could give Bayer painkiller an edge over Pfizer. More | Follow @TracyStaton

@EricPFierce: The engagement is off for CFR and Adcock Ingram. Is a spurned suitor in the wings? News | Follow @EricPFierce

@GalenMoore: Painkillers: A heart-risk warning in place since Vioxx could get lifted--for just one drug. Story | Follow @GalenMoore

> FDA panel could give Bayer painkiller an edge over rivals from Pfizer, J&J. Piece

> Government call for more HPV vaccination could boost GSK and Merck. Story

> Should Teva take a break-up cue from Big Pharma? Goldman analyst says yes. More

> FDA Commissioner's India visit coincides with trade actions. News

> Feds put Teva's Copaxone, Azilect marketing under FCA microscope. Item

CRO News

> Covance's sales soar on a jump in late-stage testing. News

> AstraZeneca spares its WuXi-partnered drug in an R&D slash and burn. Story

> BioOutsource doubles its capacity in a bet on the biosimilars boom. Article

> Wellcome bets $4M on CRO Selcia's university team-up. News

> BioClinica plots an EU expansion in the midst of its latest merger. Article

> Report: CRO biz set for another boom. Item

Biotech IT News

> > Report: Boston Scientific, Medtronic and St. Jude's networks hacked last year. Story

> Big Pharma players team with NIH to build a diabetes genomics database. Article

> The FDA is making adverse event and recall data available to app developers. Story

> U.K.'s medical research council commits $52M to medical record bioinformatics. News

> The FDA will break up its electronic submission guidance into a series of documents. Article

> Oracle is bringing Siri-like speech recognition to clinical trials. Item

Suggested Articles

Eli Lilly is closing down its U.K.-based Erl Wood neuroscience in Surrey, leading to cuts and relocations.

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.

The series A round sets Abalos up to generate anti-tumoral virus strains and take them toward testing in humans.